

Diasome Pharmaceuticals Completes Enrollment in Phase 2b OPTI-2 Trial of HDV-Insulin Lispro for Type 1 Diabetes

Phase 2b OPTI-2 trial to assess liver-targeted insulin's ability to reduce hypoglycemia and improve postprandial control using Dexcom G7 CGM data

CLEVELAND, OH, UNITED STATES, June 19, 2025 /EINPresswire.com/ -- [Diasome](#) Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company advancing portal-hepatic targeted therapies for metabolic diseases,

“

Reaching full enrollment is an important milestone for people who rely on insulin every day, and it is a significant step forward in the continued clinical development of HDV Insulin,”

Robert Geho, CEO

today announced that it has completed enrollment (n = 227) in its Phase 2b OPTI-2 trial evaluating HDV-Insulin Lispro in adults with Type 1 diabetes.

OPTI-2 is a randomized, double-blind, active control study comparing Diasome's Hepatocyte Directed Vesicle (HDV™) enabled insulin lispro to conventional lispro injected subcutaneously over a six-month treatment period. All study participants are utilizing Dexcom G7 continuous glucose monitors throughout the course of treatment to

capture detailed glycemic endpoints.

“Reaching full enrollment is an important milestone for people who rely on insulin every day, and it is a significant step forward in the continued clinical development of HDV Insulin,” said Robert Geho, Chief Executive Officer of Diasome. “OPTI-2 is designed to show that by directing insulin to the liver, where glucose regulation begins, we can meaningfully reduce hypoglycemia and improve post-meal glycemic control. We look forward to reporting topline data early in 2026.”

OPTI-2 is designed to demonstrate that liver-targeted HDV-Insulin can widen the therapeutic window of mealtime insulin by reducing the risk of hypoglycemia while maintaining glycemic control. The trial is being conducted at 26 sites in the United States.

About Diasome Pharmaceuticals

Diasome Pharmaceuticals is developing HDV™—a proprietary phospholipid system that delivers native peptides, proteins, and hormones directly to the portal-hepatic axis, the body's primary site of glucose and lipid regulation that current therapies often fail to reach. The company is

advancing first-in-class therapies designed to enhance the efficacy, safety, and durability of treatment for diabetes, obesity, and related metabolic disorders.

Media Related Inquiry
Diasome Pharmaceuticals
+1 216-444-7110
[email us here](#)

This press release can be viewed online at: <https://www.einpresswire.com/article/823768359>

EIN Presswire's priority is source transparency. We do not allow opaque clients, and our editors try to be careful about weeding out false and misleading content. As a user, if you see something we have missed, please do bring it to our attention. Your help is welcome. EIN Presswire, Everyone's Internet News Presswire™, tries to define some of the boundaries that are reasonable in today's world. Please see our Editorial Guidelines for more information.

© 1995-2025 Newsmatics Inc. All Right Reserved.